Literature DB >> 19152174

Dasatinib in relapsed or plateau-phase multiple myeloma.

Tanya M Wildes1, Elizabeth Procknow, Feng Gao, John F Dipersio, Ravi Vij.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19152174     DOI： 10.1080/10428190802563363

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  8 in total

Review 1.  Future agents and treatment directions in multiple myeloma.

Authors:  Enrique M Ocio; Constantine S Mitsiades; Robert Z Orlowski; Kenneth C Anderson
Journal:  Expert Rev Hematol       Date:  2013-12-18       Impact factor: 2.929

Review 2.  New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).

Authors:  E M Ocio; P G Richardson; S V Rajkumar; A Palumbo; M V Mateos; R Orlowski; S Kumar; S Usmani; D Roodman; R Niesvizky; H Einsele; K C Anderson; M A Dimopoulos; H Avet-Loiseau; U-H Mellqvist; I Turesson; G Merlini; R Schots; P McCarthy; L Bergsagel; C S Chim; J J Lahuerta; J Shah; A Reiman; J Mikhael; S Zweegman; S Lonial; R Comenzo; W J Chng; P Moreau; P Sonneveld; H Ludwig; B G M Durie; J F S Miguel
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

3.  Renal cell carcinoma bone metastases: clinical advances.

Authors:  Chakshu Sahi; Jennifer J Knox; Mark Clemons; Anthony M Joshua; Reuben Broom
Journal:  Ther Adv Med Oncol       Date:  2010-03       Impact factor: 8.168

4.  Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series.

Authors:  Brett Stevens; Julia Maxson; Jeffrey Tyner; Clayton A Smith; Jonathan A Gutman; William Robinson; Craig T Jordan; Choon-Kee Lee; Karen Swisshelm; Jennifer Tobin; Qi Wei; Jeffrey Schowinsky; Sean Rinella; Hea Gie Lee; Daniel A Pollyea
Journal:  Leuk Lymphoma       Date:  2015-10-27

5.  Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.

Authors:  Shin-Ichiro Fujiwara; Yuya Shirato; Takashi Ikeda; Shin-Ichiro Kawaguchi; Yumiko Toda; Shoko Ito; Shin-Ichi Ochi; Takashi Nagayama; Kiyomi Mashima; Kento Umino; Daisuke Minakata; Hirofumi Nakano; Kaoru Morita; Ryoko Yamasaki; Yasufumi Kawasaki; Miyuki Sugimoto; Masahiro Ashizawa; Chihiro Yamamoto; Kaoru Hatano; Kazuya Sato; Iekuni Oh; Ken Ohmine; Kazuo Muroi; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2017-11-28       Impact factor: 2.490

Review 6.  Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms.

Authors:  Nadine Kutsch; Reinhard Marks; Richard Ratei; Thomas K Held; Martin Schmidt-Hieber
Journal:  Biomark Insights       Date:  2015-08-16

7.  SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.

Authors:  Roy Heusschen; Joséphine Muller; Marilène Binsfeld; Caroline Marty; Erwan Plougonven; Sophie Dubois; Nadia Mahli; Karen Moermans; Geert Carmeliet; Angélique Léonard; Frédéric Baron; Yves Beguin; Eline Menu; Martine Cohen-Solal; Jo Caers
Journal:  Oncotarget       Date:  2016-05-24

Review 8.  Kinase inhibitors as potential agents in the treatment of multiple myeloma.

Authors:  Hanley N Abramson
Journal:  Oncotarget       Date:  2016-12-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.